Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial

Aim This study assessed the efficacy and safety of co‐administering retagliptin and henagliflozin versus individual agents at corresponding doses in patients with type 2 diabetes mellitus who were inadequately controlled with metformin. Methods This multicentre, phase 3 trial consisted of a 24‐week,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2024-07, Vol.26 (7), p.2774-2786
Hauptverfasser:	Wang, Yao, Jiang, Chengxia, Dong, Xiaolin, Chen, Mingwei, Gu, Qin, Zhang, Lihui, Fu, Yanqin, Pan, Tianrong, Bi, Yan, Song, Weihong, Xu, Jing, Lu, WeiPing, Sun, Xiaodong, Ye, Zi, Zhang, Danli, Peng, Liang, Lin, Xiang, Dai, Wei, Wang, Quanren, Yang, Wenying
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Blood pressure Body weight clinical trial Diabetes Diabetes mellitus (non-insulin dependent) dipeptidyl peptidase‐4 inhibitor Hemoglobin Hypoglycemia Metformin sodium‐glucose cotransporter 2 inhibitor type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!